Vincerx Pharma, Inc. (VINC)
| Market Cap | 295.14M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -10.72M |
| Shares Out | 17.51M |
| EPS (ttm) | -2.04 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | May 14 |
| Last Price | $16.86 |
| Previous Close | $16.34 |
| Change ($) | 0.52 |
| Change (%) | 3.18% |
| Day's Open | 16.13 |
| Day's Range | 16.13 - 17.07 |
| Day's Volume | 34,785 |
| 52-Week Range | 9.35 - 26.75 |
Dose escalation study in patients with CLL relapsed/refractory to venetoclax and BTK inhibitors on track to initiate in 2H2021
VIP236 shows enhanced tumor targeting with robust antitumor activity across multiple xenograft models
PALO ALTO, Calif., April 07, 2021 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradig...
PALO ALTO, Calif., April 05, 2021 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC) (the “Company”), today announced that it will redeem all of its outstanding public warrants (the “Public Warrant...
PALO ALTO, Calif., April 01, 2021 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradig...
License agreement with Bayer AG secures oncology portfolio including clinical-stage PTEFb/CDK9 inhibitor with encouraging Phase 1 activity
PALO ALTO, Calif., March 10, 2021 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradig...
PALO ALTO, Calif., Jan. 07, 2021 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm...
Business combination transaction with LifeSci Acquisition Corp. was completed on December 23, 2020
About VINC
Vincerx Pharma, Inc., a clinical-stage biopharmaceutical company, researches and develops new therapies to address unmet medical needs for the treatment of cancer. The company's lead product candidate is VIP152 that is in clinical trials. Its drug candidates are in development for the treatment of solid tumors, leukemia, B-cell malignancies, lymphomas, and myelodysplastic syndrome. Vincerx Pharma, Inc. is based in Palo Alto, California.
| Industry Biotechnology | Founded 2019 |
| Stock Exchange NASDAQ | Ticker Symbol VINC |
Analyst Forecasts
According to one analyst, the rating for Vincerx Pharma stock is "Strong Buy" and the 12-month stock price forecast is 33.00.